STOCK TITAN

PDS Biotechnology Corporation (PDSB) Stock News

PDSB NASDAQ

PDS Biotechnology Corporation reports developments in targeted cancer immunotherapies based on its Versamune platform. Company news centers on PDS0101, also called Versamune HPV, in HPV16-positive head and neck cancer, and on PDS01ADC, an IL-12 fused antibody drug conjugate and tumor-targeted immunocytokine evaluated across multiple solid tumor indications.

Recurring updates include clinical-trial data, National Cancer Institute-led study presentations, FDA and IND protocol communications, scientific publications, patent coverage for core technology, quarterly financial results, and broader corporate-program updates.

Rhea-AI Summary

PDS Biotechnology (Nasdaq: PDSB) reported a narrower third-quarter 2026 net loss while continuing to prioritize PDS0301 as its lead development program. Net loss was $7.6 million, or $0.11 per share, versus $9.0 million, or $0.19 per share, a year earlier. Research and development expenses fell to $2.1 million from $4.6 million; general and administrative expenses rose to $3.8 million from $3.6 million. Net interest expense increased to $1.7 million from $0.9 million.

Cash was $15,245,081 at September 30, versus $26,711,969 at December 31, 2025. The initial closing of a PIPE private financing of up to $22.3 million, led by Nant Capital, was completed during the quarter. A further closing depends on submitting a PDS0301 Phase 3 protocol to the FDA and applicable closing conditions. PDS0101 Phase 2 results were published in JAMA Oncology, and patents issued in Japan, India and Israel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.96%
Tags
-
Rhea-AI Summary

PDS Biotech (Nasdaq: PDSB) received approximately $3.9 million in gross proceeds after NantWorks exercised its outstanding common stock warrants.

The exercise covered 17,699,115 shares, or pre-funded warrants instead, at $0.22 per share. Amounts exceeding the nonwaivable 19.9% beneficial ownership limit were exercised for pre-funded warrants, which carry a $0.00033 exercise price and do not expire. The company intends to use net proceeds, together with net proceeds from its September 2026 private placement, to advance PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and support its PDS0101 partnership strategy and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
-
Rhea-AI Summary

PDS Biotechnology (Nasdaq: PDSB) appointed John Dawson, Deborah Ramsdell and Bruce Wendel to its board of directors, effective October 18, 2026. The appointments follow the resignations of Stephen Glover, Kamil Ali-Jackson, Gregory Freitag and Otis Brawley, effective the same date.

The company expects the new directors' drug development, commercialization, regulatory and partnership experience to support its plans to advance PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and pursue potential partnerships for PDS0101.

The reconstituted Audit Committee is chaired by James Banaag, with Dawson and Wendel as members. Patrick Soon-Shiong chairs the Compensation Committee, joined by Banaag and Dawson. Wendel chairs the Nominating and Governance Committee, alongside Ramsdell and Ilian Iliev.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.80%
Tags
management
Rhea-AI Summary

PDS Biotech (Nasdaq: PDSB) will host a virtual event on PDS0301 in advanced colorectal cancer with liver metastases on October 15, 2026. The event begins at 8:00 AM ET and features Jonathan M. Hernandez, M.D., an investigator in the National Cancer Institute’s Center for Cancer Research Surgical Oncology Program.

Hernandez and company management will discuss Phase 2 clinical outcomes in advanced liver-associated cancers, focusing on the metastatic colorectal cancer cohort. The overview will cover patients receiving second- and third-line treatment for colorectal liver metastases that cannot be surgically removed and have microsatellite-stable or mismatch repair-proficient disease. A live question-and-answer session will follow.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.92%
Tags
none
-
Rhea-AI Summary

PDS Biotech (PDSB) reported Phase 2 VERSATILE-002 results for HPV16-targeted immunotherapy PDS0101 plus pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma, now published in JAMA Oncology.

In immune checkpoint inhibitor (ICI)-naïve patients with PD-L1 CPS ≥ 1 (mITT n = 53), median overall survival was 39.3 months (95% CI, 23.9 to NE), compared with a best published 17.9 months for standard-of-care pembrolizumab-based regimens (no head-to-head data). Objective response rate in CPS ≥ 1 was 36% (investigator review; 5 complete responses) and 34% (central review; 6 complete responses), versus a published 19% ORR for pembrolizumab alone in a similar CPS ≥ 1 population. Grade ≥ 3 treatment-related adverse events occurred in 13.8% of patients, with one Grade 4 event and no Grade 5 events, compared with 17% Grade ≥ 3 TRAEs for pembrolizumab standard-of-care.

The open-label, non-randomized trial enrolled 88 patients across 26 centers in the US, UK and Ireland; 75 formed the mITT efficacy population, including 53 ICI-naïve and 22 ICI-resistant patients. PDS Biotech continues to prioritize its PDS0301 program in metastatic colorectal cancer and is pursuing a partnership strategy for PDS0101. The company recently closed an initial tranche of a PIPE financing of up to $22.3 million, led by Nant Capital, and granted NantWorks a one-year exclusive right to negotiate an exclusive PDS0101 license.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
-
Rhea-AI Summary

PDS Biotechnology (PDSB) closed an initial tranche of a PIPE financing on September 14, 2026, raising gross proceeds of approximately $11.3 million led by Nant Capital, with Dr. Patrick Soon-Shiong joining its board.

At the Initial Closing, the company issued 16,502,870 common shares, 23,498,156 pre-funded warrants and 20,000,514 common warrants, at unit prices of $0.2825 per share-and-warrant unit and $0.28217 per pre-funded-and-warrant unit. A contingent Milestone Closing would add $10 million from Nant and $1 million from AB Group Ltd., triggered by submission to the FDA of a registrational Phase 3 protocol for PDS0301 designed with Nant, subject to closing conditions and a 19.9% beneficial ownership cap per investor.

The funds are intended for debt repayment, working capital and clinical development, including advancing PDS0301, which in an NCI-led Phase 2 trial in 22 MSS/pMMR mCRC patients showed good tolerability and 80% 24‑month survival. NantWorks also received a one‑year exclusive right to negotiate an exclusive license to HPV‑targeted immunotherapy PDS0101, and James Banaag of NantBio also joined the PDS board.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.33%
Tags
management
Rhea-AI Summary

PDS Biotechnology (PDSB) agreed to a PIPE financing of up to $22.55 million led by Nant Capital, alongside existing investors.

The PIPE has an Initial Closing of about $11.55 million, expected on or about September 11, 2026, and a Milestone Closing of $11 million tied to submission of a registrational Phase 3 protocol for PDS0301 to the FDA. Initial units combine one common share and a warrant to purchase half a share at $0.2825, or a pre-funded warrant plus half-share warrant at $0.28217, for an expected issuance of 20,875,220 common shares, 20,009,736 pre-funded warrants and 20,442,479 common warrants.

Nant may designate two directors, including Dr. Patrick Soon‑Shiong, while it owns at least 15% of the common stock. The company plans to advance PDS0301 into late-stage development, supported by NCI-led Phase 2 data in MSS/pMMR metastatic colorectal cancer where adding PDS0301 yielded 80% 24‑month survival in 22 patients. Proceeds will repay debt and fund clinical programs and corporate needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.36%
Tags
none
-
Rhea-AI Summary

PDS Biotechnology (Nasdaq:PDSB) reported Q2 2026 net loss of $9.8 million, or $0.18 per share, versus $9.4 million, or $0.21, a year earlier. Total operating expenses fell to $6.5 million from $7.6 million, while net interest expense increased to $3.3 million from $1.8 million, mainly due to a non-cash loss on retirement of debt.

The company highlighted positive Stage 1 data from an NCI-led Phase 2 metastatic colorectal cancer trial of its IL-12 immunocytokine PDS0301, including a 77.8% six-month objective response rate and approximately 80% 24-month survival. Following a strategic review, PDS Biotech is prioritizing PDS0301 as its lead program, discontinuing internal investment in PDS0101 and the VERSATILE-003 Phase 3 trial while seeking partnerships for PDS0101. As of June 30, 2026, cash was $5.6 million, working capital was negative $5.3 million and stockholders’ equity was negative $3.6 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
-
Rhea-AI Summary

PDS Biotechnology (Nasdaq:PDSB) announced a strategic refocus following a portfolio and capital allocation review, prioritizing its tumor-targeted IL‑12 immunocytokine PDS0301 and pursuing partnership-driven development for PDS0101. The company will cease internal investment in, and discontinue, the PDS0101 Phase 3 VERSATILE‑003 trial.

According to PDS Biotech, Phase 2 data in metastatic MSS/pMMR colorectal cancer with liver metastases showed a 71% objective response rate at 6 months and 80% 24‑month survival, with safety observed in more than 380 treated patients. A randomized Phase 2b mCRC program has been designed incorporating FDA feedback. Over the next 18–24 months, the company plans to advance PDS0301 through this Phase 2b program, identify strategic partners for PDS0101, and maintain disciplined capital allocation. PDS Biotech will report results for the quarter ended June 30, 2026, on August 13, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-64.87%
Tags
partnership
Rhea-AI Summary

PDS Biotech (Nasdaq:PDSB) reported Q1 2026 results and clinical updates. The VERSATILE-003 Phase 3 protocol now uses progression-free survival as an interim primary endpoint, potentially supporting accelerated approval of PDS0101, while overall survival remains the primary endpoint for full approval.

Stage 1 data for PDS01ADC in metastatic colorectal cancer showed 77.8% ORR (7/9) and ~85% 24‑month survival. Early metastatic castration-resistant prostate cancer data reported median PFS of 9.6 months. New U.S. and Japan patents extend PDS0101 protection into the 2040s. Q1 2026 net loss was $7.3M ($0.13/share) versus $8.5M ($0.21/share) a year earlier; operating expenses were $6.5M, and cash was $21.7M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.91%
Tags

FAQ

What is the current stock price of PDS Biotechnology (PDSB)?

PDS Biotechnology (PDSB) last closed at $0.7774.

What is the market cap of PDS Biotechnology (PDSB)?

The market cap of PDS Biotechnology (PDSB) is approximately $95.4M.